These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
65 related articles for article (PubMed ID: 20158108)
1. [PPARgamma antagonist as a potential drug for the treatment of obesity and diabetes]. Waki H; Yamauchi T; Kadowaki T Nihon Rinsho; 2010 Feb; 68(2):350-5. PubMed ID: 20158108 [TBL] [Abstract][Full Text] [Related]
2. Antagonism of peroxisome proliferator-activated receptor gamma prevents high-fat diet-induced obesity in vivo. Nakano R; Kurosaki E; Yoshida S; Yokono M; Shimaya A; Maruyama T; Shibasaki M Biochem Pharmacol; 2006 Jun; 72(1):42-52. PubMed ID: 16696951 [TBL] [Abstract][Full Text] [Related]
3. Berberine improves free-fatty-acid-induced insulin resistance in L6 myotubes through inhibiting peroxisome proliferator-activated receptor gamma and fatty acid transferase expressions. Chen Y; Li Y; Wang Y; Wen Y; Sun C Metabolism; 2009 Dec; 58(12):1694-702. PubMed ID: 19767038 [TBL] [Abstract][Full Text] [Related]
5. The Pro12Ala polymorphism in PPAR gamma2 may confer resistance to type 2 diabetes. Hara K; Okada T; Tobe K; Yasuda K; Mori Y; Kadowaki H; Hagura R; Akanuma Y; Kimura S; Ito C; Kadowaki T Biochem Biophys Res Commun; 2000 Apr; 271(1):212-6. PubMed ID: 10777704 [TBL] [Abstract][Full Text] [Related]
6. Plasma cell membrane glycoprotein 1 (PC-1): a marker of insulin resistance in obesity, uremia and diabetes mellitus. Stefanović V; Antić S Clin Lab; 2004; 50(5-6):271-8. PubMed ID: 15209435 [TBL] [Abstract][Full Text] [Related]
7. Review: peroxisome proliferator-activated receptor-gamma and its role in the development and treatment of diabetes. Leff T; Mathews ST; Camp HS Exp Diabesity Res; 2004; 5(2):99-109. PubMed ID: 15203881 [TBL] [Abstract][Full Text] [Related]
8. [The molecular mechanisms by which PPAR gamma/RXR inhibitors improve insulin resistance]. Yamauchi T; Kadowaki T Nihon Rinsho; 2001 Nov; 59(11):2245-54. PubMed ID: 11712415 [TBL] [Abstract][Full Text] [Related]
9. The effects of obesity-associated insulin resistance on mRNA expression of peroxisome proliferator-activated receptor-gamma target genes, in dogs. Gayet C; Leray V; Saito M; Siliart B; Nguyen P Br J Nutr; 2007 Sep; 98(3):497-503. PubMed ID: 17475082 [TBL] [Abstract][Full Text] [Related]
10. Effect of heterozygous PPARgamma deficiency and TZD treatment on insulin resistance associated with age and high-fat feeding. Miles PD; Barak Y; Evans RM; Olefsky JM Am J Physiol Endocrinol Metab; 2003 Mar; 284(3):E618-26. PubMed ID: 12556354 [TBL] [Abstract][Full Text] [Related]
11. The many faces of PPARgamma. Lehrke M; Lazar MA Cell; 2005 Dec; 123(6):993-9. PubMed ID: 16360030 [TBL] [Abstract][Full Text] [Related]
12. The role of PPARgamma in high-fat diet-induced obesity and insulin resistance. Kadowaki T; Hara K; Kubota N; Tobe K; Terauchi Y; Yamauchi T; Eto K; Kadowaki H; Noda M; Hagura R; Akanuma Y J Diabetes Complications; 2002; 16(1):41-5. PubMed ID: 11872365 [TBL] [Abstract][Full Text] [Related]
13. Weight-loss-associated induction of peroxisome proliferator-activated receptor-alpha and peroxisome proliferator-activated receptor-gamma correlate with reduced atherosclerosis and improved cardiovascular function in obese insulin-resistant mice. Verreth W; De Keyzer D; Pelat M; Verhamme P; Ganame J; Bielicki JK; Mertens A; Quarck R; Benhabilès N; Marguerie G; Mackness B; Mackness M; Ninio E; Herregods MC; Balligand JL; Holvoet P Circulation; 2004 Nov; 110(20):3259-69. PubMed ID: 15533870 [TBL] [Abstract][Full Text] [Related]
14. Lack of association between the Pro12Ala polymorphism in PPAR-gamma2 gene and body weight changes, insulin resistance and chronic diabetic complications in obese patients with type 2 diabetes. Stefanski A; Majkowska L; Ciechanowicz A; Frankow M; Safranow K; Parczewski M; Pilarska K Arch Med Res; 2006 Aug; 37(6):736-43. PubMed ID: 16824933 [TBL] [Abstract][Full Text] [Related]
15. PAR-5359, a well-balanced PPARalpha/gamma dual agonist, exhibits equivalent antidiabetic and hypolipidemic activities in vitro and in vivo. Kim MK; Chae YN; Son MH; Kim SH; Kim JK; Moon HS; Park CS; Bae MH; Kim E; Han T; Choi HH; Shin YA; Ahn BN; Lee CH; Lim JI; Shin CY Eur J Pharmacol; 2008 Oct; 595(1-3):119-25. PubMed ID: 18727927 [TBL] [Abstract][Full Text] [Related]
16. Peroxisome proliferator-activated receptor-alpha,gamma-agonist improves insulin sensitivity and prevents loss of left ventricular function in obese dyslipidemic mice. Verreth W; Ganame J; Mertens A; Bernar H; Herregods MC; Holvoet P Arterioscler Thromb Vasc Biol; 2006 Apr; 26(4):922-8. PubMed ID: 16456093 [TBL] [Abstract][Full Text] [Related]
17. The establishment of a novel non-alcoholic steatohepatitis model accompanied with obesity and insulin resistance in mice. Cong WN; Tao RY; Tian JY; Liu GT; Ye F Life Sci; 2008 May; 82(19-20):983-90. PubMed ID: 18417155 [TBL] [Abstract][Full Text] [Related]